A Phase 2 interventional study of Dulaglutide and Placebo in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 66 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-23.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 20th largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 2, and was the 33rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 318 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 90th largest by enrollment of the 232 interventional ones that give a count, is one of 7 that started in 2016, is one of 34 in phase 2, and was the 124th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4.5mg of Dulaglutide administered subcutaneously (SC)
Drug: Dulaglutide
3.0mg of Dulaglutide administered SC
Drug: Dulaglutide
1.5mg of Dulaglutide administered SC
Drug: Dulaglutide
Placebo administered SC
Drug: Placebo
Administered SC
Also known as: LY2189265
Administered SC
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, treatment, time, treatment\*time as fixed effects.
Time frame: Baseline, Week 18
Percentage of Participants With HbA1c of <7.0%
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Week 18
Change From Baseline in Fasting Serum Glucose (FSG)
Fasting serum glucose (FSG) is a test to determine how much glucose (sugar) is in a serum sample after an overnight fast. Least Squares (LS) means was determined by MMRM methodology with baseline as a covariate, pooled country, baseline HbA1c strata using \>=8% as cutoff, treatment, time, treatment\*time as fixed effects.
Time frame: Baseline, Week 18
Change From Baseline in Body Weight
Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, baseline HbA1c strata using \>=8% as cutoff, treatment, time, treatment\*time as fixed effects.
Time frame: Baseline, Week 18
Percentage of Participants Discontinuing Study Drug Due to Adverse Events
Adverse event (AE) defined as any unfavorable medical event, newly emerged or a deterioration of a preexisting condition, in other words any untoward medical occurrence in a patient administered a pharmaceutical product, without regard to the possibility of a causal relationship, that occurred after the visit for informed consent and up to the visit for completion of administration, or discontinuation.
Time frame: Baseline through Week 18
Rate of Documented Symptomatic Hypoglycemia
Hypoglycemic events (HE) were classified as severe, documented symptomatic (defined as an HE with typical symptoms of hypoglycemia and a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]). Hypoglycemia rate per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia was analyzed using a generalized estimation equations model with a negative binomial distribution and a Log link. LS mean was determined by MMRM methodology with baseline hypoglycemia rate, pooled country, HbA1c at Baseline, treatment, with log of exposure in days divided by 365.25 as the offset.
Time frame: Week 18
Pharmacokinetics (PK): The Maximum Drug Concentration at Steady State (Cmax,ss) of Dulaglutide
Plasma samples for PK analysis were combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit. Cmax takes all time points post dose into account and one value was reported.
Time frame: 0, 2, 4, 6, 10, 18, 22 weeks and early termination
Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide
AUC\[0-168h\] is a combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit.
Time frame: 0, 2, 4, 6, 10, 18, 22 weeks and early termination
The study consisted of 3 periods: an approximately 2-week lead-in period, followed by an 18-week treatment period, and a 4-week safety follow-up period.
| Milestone | Placebo | Dulaglutide 1.5 Milligrams (mg) | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|---|
| Started | 82 | 81 | 79 | 76 |
| Received at least 1 dose of study drug | 81 | 81 | 79 | 76 |
| Completed | 75 | 73 | 75 | 69 |
| Not completed | 7 | 8 | 4 | 7 |
| Withdrew: Adverse event | 1 | 2 | 1 | 2 |
| Withdrew: Lost to follow-up | 3 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 5 | 1 | 4 |
| Withdrew: Notification of change in address | 0 | 0 | 0 | 1 |
| Withdrew: Failed to attend safety followup period | 0 | 0 | 1 | 0 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, treatment, time, treatment\*time as fixed effects.
| Percentage of glycosylated hemoglobin | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -0.44 ± 0.101 | -1.23 ± 0.099 | -1.31 ± 0.099 | -1.40 ± 0.103 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
| Percentage of Participants | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|---|
| Percentage of Participants With HbA1c of <7.0% | 20 | 71.2 | 71.2 | 68.2 |
Fasting serum glucose (FSG) is a test to determine how much glucose (sugar) is in a serum sample after an overnight fast. Least Squares (LS) means was determined by MMRM methodology with baseline as a covariate, pooled country, baseline HbA1c strata using \>=8% as cutoff, treatment, time, treatment\*time as fixed effects.
| millimole/liter (mmol/L) | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) | -0.69 ± 0.257 | -2.01 ± 0.261 | -1.92 ± 0.250 | -2.11 ± 0.263 |
Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline as a covariate, pooled country, baseline HbA1c strata using \>=8% as cutoff, treatment, time, treatment\*time as fixed effects.
| Kilograms (Kg) | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|---|
| Change From Baseline in Body Weight | -1.6 ± 0.39 | -2.8 ± 0.39 | -3.9 ± 0.39 | -4.1 ± 0.41 |
Adverse event (AE) defined as any unfavorable medical event, newly emerged or a deterioration of a preexisting condition, in other words any untoward medical occurrence in a patient administered a pharmaceutical product, without regard to the possibility of a causal relationship, that occurred after the visit for informed consent and up to the visit for completion of administration, or discontinuation.
| Percentage of Participants | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|---|
| Percentage of Participants Discontinuing Study Drug Due to Adverse Events | 4.9 | 6.2 | 10.1 | 13.2 |
Hypoglycemic events (HE) were classified as severe, documented symptomatic (defined as an HE with typical symptoms of hypoglycemia and a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]). Hypoglycemia rate per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia was analyzed using a generalized estimation equations model with a negative binomial distribution and a Log link. LS mean was determined by MMRM methodology with baseline hypoglycemia rate, pooled country, HbA1c at Baseline, treatment, with log of exposure in days divided by 365.25 as the offset.
| Episodes/participant/365.25 days | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|---|
| Rate of Documented Symptomatic Hypoglycemia | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.001 |
Plasma samples for PK analysis were combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit. Cmax takes all time points post dose into account and one value was reported.
| nanogram per milliliter (ng/mL) | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|
| Pharmacokinetics (PK): The Maximum Drug Concentration at Steady State (Cmax,ss) of Dulaglutide | 90.4 (38.9 to 170) | 151 (64.3 to 277) | 204 (87.2 to 377) |
AUC\[0-168h\] is a combined measure obtained from 0, 2, 4, 6, 10, 18, 22 weeks and until early termination of the visit.
| nanogram*hour per milliliter (ng*h/mL) | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|
| Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 168 Hours (AUC[0-168], ss) of Dulaglutide | 11800 (5300 to 21300) | 26700 (15300 to 41400) | 36600 (21100 to 56500) |
Collected over Up to 22 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/81 (0%) | 4/81 (4.9%) | 29/81 (35.8%) |
| Dulaglutide 1.5mg | 0/81 (0%) | 3/81 (3.7%) | 36/81 (44.4%) |
| Dulaglutide 3.0mg | 0/79 (0%) | 7/79 (8.9%) | 49/79 (62%) |
| Dulaglutide 4.5mg | 0/76 (0%) | 3/76 (3.9%) | 39/76 (51.3%) |
| Event | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 0/81 | 0/81 | 0/79 | 1/76 |
| PancreatitisGastrointestinal disorders | 0/81 | 0/81 | 0/79 | 1/76 |
| CholecystitisHepatobiliary disorders | 0/81 | 0/81 | 0/79 | 1/76 |
| Cholecystitis acuteHepatobiliary disorders | 0/81 | 0/81 | 0/79 | 1/76 |
| BronchitisInfections and infestations | 0/81 | 0/81 | 0/79 | 1/76 |
| Atrioventricular block second degreeCardiac disorders | 0/81 | 0/81 | 1/79 | 0/76 |
| VomitingGastrointestinal disorders | 0/81 | 0/81 | 1/79 | 0/76 |
| Cholecystitis infectiveInfections and infestations | 0/81 | 0/81 | 1/79 | 0/76 |
| Fungal oesophagitisInfections and infestations | 0/81 | 0/81 | 1/79 | 0/76 |
| Peritonsillar abscessInfections and infestations | 0/81 | 0/81 | 1/79 | 0/76 |
| Event | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/81 | 18/81 | 20/79 | 23/76 |
| DiarrhoeaGastrointestinal disorders | 9/81 | 9/81 | 18/79 | 16/76 |
| Decreased appetiteMetabolism and nutrition disorders | 1/81 | 3/81 | 13/79 | 6/76 |
| VomitingGastrointestinal disorders | 4/81 | 9/81 | 9/79 | 10/76 |
| HeadacheNervous system disorders | 7/81 | 4/81 | 10/79 | 5/76 |
| DyspepsiaGastrointestinal disorders | 0/81 | 6/81 | 5/79 | 8/76 |
| Abdominal painGastrointestinal disorders | 1/81 | 3/81 | 1/79 | 7/76 |
| FatigueGeneral disorders | 2/81 | 1/81 | 4/79 | 7/76 |
| ConstipationGastrointestinal disorders | 0/81 | 5/81 | 4/79 | 6/76 |
| EructationGastrointestinal disorders | 0/81 | 3/81 | 1/79 | 6/76 |
| Age, Continuous(Years) | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg | Total |
|---|---|---|---|---|---|
| Mean | 56.52 ± 8.93 | 57.65 ± 9.79 | 55.90 ± 10.74 | 57.13 ± 9.63 | 56.80 ± 9.77 |
| Sex: Female, Male(Participants) | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg | Total |
|---|---|---|---|---|---|
| Female | 33 | 42 | 44 | 40 | 159 |
| Male | 48 | 39 | 35 | 36 | 158 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 35 | 32 | 38 | 30 | 135 |
| Not Hispanic or Latino | 46 | 49 | 40 | 45 | 180 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 10 | 6 | 9 | 6 | 31 |
| Asian | 0 | 0 | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 6 | 6 | 6 | 6 | 24 |
| White | 59 | 68 | 58 | 59 | 244 |
| More than one race | 5 | 1 | 4 | 2 | 12 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg | Total |
|---|---|---|---|---|---|
| Romania | 6 | 6 | 5 | 4 | 21 |
| United States | 42 | 45 | 44 | 43 | 174 |
| Czechia | 10 | 9 | 10 | 8 | 37 |
| Poland | 13 | 11 | 10 | 10 | 44 |
| Mexico | 10 | 10 | 10 | 11 | 41 |
| Baseline Hemoglobin A1c (HbA1c)(Percentage of glycosylated hemoglobin) | Placebo | Dulaglutide 1.5mg | Dulaglutide 3.0mg | Dulaglutide 4.5mg | Total |
|---|---|---|---|---|---|
| Mean | 8.08 ± 0.79 | 8.02 ± 0.80 | 8.16 ± 0.92 | 8.12 ± 0.81 | 8.09 ± 0.83 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Dec 2016, a primary completion of Jul 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide